ClinicalTrials.gg
CompletedNCT04058158Updated Mar 26, 2024Results posted

A Study to Compare SB12 (Proposed Eculizumab Biosimilar) to Soliris in Subjects With Paroxysmal Nocturnal Haemoglobinuria

A Phase 3 interventional study of SB12 (proposed eculizumab biosimilar) and Soliris (eculizumab) in Paroxysmal Nocturnal Hemoglobinuria, sponsored by Samsung Bioepis Co., Ltd.. Completed at 27 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-03-26.

Sponsored by Samsung Bioepis Co., Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 18 studies testing eculizumab in Hemoglobinuria, Paroxysmal — none open to participants now, none under way, none of them phase 3. eculizumab · Hemoglobinuria, Paroxysmal.

Enrollment
7th of 18
50 · median 37
Started
2019
with 2 others
Phase 3
14 of 18
none open now
Registered
10th of 18
by date
Lead sponsor
1 of 18
Samsung Bioepis Co., Ltd.

Among the 18 studies testing eculizumab in Hemoglobinuria, Paroxysmal, this one is the 7th largest by enrollment, is one of 3 that started in 2019, is one of 14 in phase 3, and was the 10th registered.

Hemoglobinuria, Paroxysmal

191 studies on the registry are indexed under Hemoglobinuria, Paroxysmal; 49 are open to participants now.

Browse Hemoglobinuria, Paroxysmal studies →

Open to participants now

None of the 18 studies testing eculizumab in Hemoglobinuria, Paroxysmal is open now. The open studies under Hemoglobinuria, Paroxysmal, anywhere →

About eculizumab

eculizumab: first FDA approval 2007 (SOLIRIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 30 Hemoglobinuria, Paroxysmal studies recruiting now, 14 (47%) set no upper age limit and 12 (40%) stop at 75 or younger; 12 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 18 studies testing eculizumab in Hemoglobinuria, Paroxysmal as a file.
02

Study summary

This is a randomised Phase III, double-blind, multicentre, cross-over study to compare the efficacy, safety, pharmacokinetics, and immunogenicity between SB12 and Soliris® in subjects with PNH.

Read the detailed description

Subjects will be randomised in a 1:1 ratio to either treatment sequence. Subjects randomly assigned to treatment with SB12 or Soliris® will receive 600 mg of eculizumab IV every week for first 4 weeks (initial phase) and 900 mg for the fifth week, followed by 900 mg every 2 weeks until Week 52. Subjects who are randomised to initially receive SB12 will be switched to receive Soliris® and subjects who are randomised to initially receive Soliris® will be switched to receive SB12 at Week 26.

03

Conditions studied

  • Paroxysmal Nocturnal Hemoglobinuria
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female aged 18 or older
  • Eculizumab-naïve patients with PNH
  • Presence of the PNH white blood cell (WBC) clone ≥ 10%
  • Documented LDH level ≥ 1.5 x at Screening
  • History of transfusion for anaemia within 12 months prior to Screening or having PNH-related symptoms at Screening
  • Subjects must be vaccinated against Neisseria meningitides

Exclusion criteria

Exclusion Criteria:

  • Previous treatment with any complement pathway inhibitors
  • ANC ≤ 500/mm3 or count \< 70,000/mm3
  • History of meningococcal disease
  • History of bone marrow transplantation
  • Known or suspected active bacterial/viral/fungal infection within 30 days
  • Stable use of erythropoietic, , heparin, warfarin before randomisation
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    Treatment Sequence I

    Subjects who are randomised to initially receive SB12 will be switched to receive Soliris® at Week 26

    Drug: SB12 (proposed eculizumab biosimilar) · Drug: Soliris (eculizumab)

  • Experimental
    Treatment Sequence II

    Subjects who are randomised to initially receive Soliris® will be switched to receive SB12 at Week 26

    Drug: SB12 (proposed eculizumab biosimilar) · Drug: Soliris (eculizumab)

Interventions

  • DrugSB12 (proposed eculizumab biosimilar)

    600 mg IV every week for first 4 weeks and 900 mg for the fifth week, followed by 900 mg every 2 weeks thereafter

  • 600 mg IV every week for first 4 weeks and 900 mg for the fifth week, followed by 900 mg every 2 weeks thereafter

06

What researchers measure

Primary outcomes

  1. Lactate Dehydrogenase (U/L) at Week 26

    Time frame: Week 26

  2. Time-adjusted AUEC of LDH From Week 14 to Week 26 and From Week 40 to Week 52

    Time frame: From Week 14 to Week 26 and from Week 40 to Week 52

07

Results

Posted Mar 26, 2024

Participant flow

Period 1
Participant flow — Period 1
MilestoneSoliris to SB12SB12 to Soliris
Started2525
Completed2323
Not completed22
Withdrew: Death10
Withdrew: Adverse event11
Withdrew: Pregnancy01
Period 2
Participant flow — Period 2
MilestoneSoliris to SB12SB12 to Soliris
Started2323
Completed2323
Not completed00

Outcome measures

PrimaryLactate Dehydrogenase (U/L) at Week 26
Time frame:
Week 26
Reported as:
Least squares mean · U/L
Lactate Dehydrogenase (U/L) at Week 26
U/LSB12Soliris
Lactate Dehydrogenase (U/L) at Week 26284.20 ± 456.73249.72 ± 103.67
Statistical analysis
  • SB12 vs Soliris · Least squares mean difference: 34.48 · 95% CI -47.66 to 116.62
PrimaryTime-adjusted AUEC of LDH From Week 14 to Week 26 and From Week 40 to Week 52
Time frame:
From Week 14 to Week 26 and from Week 40 to Week 52
Reported as:
Geometric least squares mean · U/L
Time-adjusted AUEC of LDH From Week 14 to Week 26 and From Week 40 to Week 52
U/LSB12Soliris
Time-adjusted AUEC of LDH From Week 14 to Week 26 and From Week 40 to Week 52279.65 ± 325.37258.73 ± 95.09
Statistical analysis
  • SB12 vs Soliris · Ratio of geometric least squares mean: 1.08 · 90% CI 0.95 to 1.23

Adverse events

Collected over From the time of signing the informed consent form until Week 58 (EOS Visit) or ET Visit. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SB120/47 (0%)3/47 (6.4%)18/47 (38.3%)
Soliris1/47 (2.1%)2/47 (4.3%)11/47 (23.4%)
Most frequent serious events
Most frequent serious events
EventSB12Soliris
Hand fractureInjury, poisoning and procedural complications1/470/47
HaemolysisBlood and lymphatic system disorders1/470/47
Infusion site hypersensitivityGeneral disorders0/471/47
Portal vein thrombosisHepatobiliary disorders0/471/47
CellulitisInfections and infestations0/471/47
Wound infection bacterialInfections and infestations1/470/47
Most frequent other events
Most frequent other events
EventSB12Soliris
Corona virus infectionInfections and infestations8/473/47
HaemoglobinuriaRenal and urinary disorders8/472/47
DiarrhoeaGastrointestinal disorders4/472/47
Alanine aminotransferase increasedInvestigations3/472/47
HeadacheNervous system disorders2/473/47
HypertensionVascular disorders3/470/47

Baseline characteristics

Age, Continuous
Age, Continuous(years)Soliris to SB12SB12 to SolirisTotal
Mean36.3 ± 13.6740.0 ± 13.4438.1 ± 13.55
Sex: Female, Male
Sex: Female, Male(Participants)Soliris to SB12SB12 to SolirisTotal
Female14822
Male111728
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Soliris to SB12SB12 to SolirisTotal
American Indian or Alaska Native000
Asian121527
Native Hawaiian or Other Pacific Islander000
Black or African American000
White11718
More than one race000
Unknown or Not Reported235
08

Study locations

27 sites
  • Fortis Memorial Research Institute
    Gurgaon, Haryana 122002, India
  • Post Graduate Institute of Medical Education and Research (PGIMER)
    Chandigarh, India
  • Apollo Hospitals International Limited
    Chennai, India
  • Amrita Institute of Medical Sciences and Research Centre
    Cochin, India
  • Nil Ratan Sircar Medical College and Hospital
    Kolkata, India
  • Samsung Medical Center
    Seoul, Korea, Republic of
  • Seoul National University Hospital
    Seoul, Korea, Republic of
  • Hospital Ampang
    Ampang, Malaysia
  • Hospital Sultanah Aminah
    Johor Bahru, Malaysia
  • Queen Elizabeth Hospital - Kota Kinabalu
    Kota Kinabalu, Malaysia
  • Hospital Tengku Ampuan Afzan
    Kuantan, Malaysia
  • Hospital Pulau Pinang
    Pulau Pinang, Malaysia
  • Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
    Tlalpan, Mexico
  • Colentina Clinical Hospital
    Bucharest, Romania
  • Emergency University Hospital
    Bucharest, Romania
  • Prof Dr I Chiricuta Institute of Oncology
    Cluj-Napoca, Romania
  • Filantropia Municipal Clinical Hospital
    Craiova, Romania
  • National Cheng Kung University Hospital
    Tainan, Taiwan
  • National Taiwan University Hospital
    Taipei, Taiwan
  • Tri-Service General Hospital
    Taipei, Taiwan
  • Chang Gung Memorial Hospital
    Taoyuan, Taiwan
  • Chulalongkorn University
    Bangkok, Thailand
  • Srinagarind Hospital
    Nai Muang, Thailand
  • Vinnytsia Regional Clinical Hospital n.a. M.I.Pyrohov
    Vinnytsia, 'Vinnyts'ka Oblast 21018, Ukraine
  • Municipal Institution Cherkasy Regional Oncology Dispensary of Cherkasy Regional Council
    Cherkasy, 18009, Ukraine
  • Communal Non-profit Enterprise Regional Center of Oncology
    Kharkiv, Ukraine
  • Poltava Regional Clinical Hospital n.a. M.V. Sklifosovskyi
    Poltava, Ukraine
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2019 to primary completion in Sep 2021, 25 months.

Results were first posted in Mar 2024, 2 years 6 months after primary completion.

Of 35 industry-sponsored phase 3 interventional studies under Hemoglobinuria, Paroxysmal, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 41. This study's 25 months is close to that.

Counting every sponsor, half of 35 studies reached it within 23 months; a quarter within 15 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 12, 2019
First posted
Aug 15, 2019
StartActual
Aug 7, 2019
Primary completionActual
Sep 21, 2021
CompletionActual
Oct 21, 2021
Results first posted
Mar 26, 2024
Last update
Mar 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04058158
Responsible party
Sponsor
First posted
Aug 15, 2019
Start date
Aug 7, 2019
Primary completion
Sep 21, 2021
Completion
Oct 21, 2021
Results posted
Mar 26, 2024
Last update
Mar 26, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eculizumab

Start the discussion